
Empagliflozin - Chronic Kidney Disease
You are here : Home > Formulary Search > Empagliflozin - Chronic Kidney Disease
Status 1
- Tablets
Documentation
- No records returned.
PAD Profile
Dapagliflozin is the preferred SGLT-2 for CKD.
If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist team may be prudent prior to Empagliflozin initiation.
Committee Recommendations (3)
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed that dapagliflozin will be the preferred SGLT-2 inhibitor in type 2 diabetes, Chronic Kidney Disease and Heart Failure.
The Medicines safety Committee has approved the 'Getting the most from your SGLT2 inhibitor (‘gliflozin’) medicine' PIL which can be adapted for use by services.
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves empagliflozin as a treatment option for treating chronic kidney disease in line with NICE TA942.
NB: Check NICE guidance for recommended patient cohorts regarding eGFR.
Empagliflozin will be considered GREEN on the traffic light system.
Key considerations:
- If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist diabetes team may be prudent prior to empagliflozin initiation.
Other Indications
Below are listed other indications that Empagliflozin is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Chronic Kidney Disease.